Medicare to Cover GLP-1 Weight-Loss Drugs Starting July 1
Qualifying Medicare beneficiaries will gain access to GLP-1 weight-loss medications for $50/month. Here's what older Americans should know first.
For the first time, millions of older Americans enrolled in Medicare will have access to GLP-1 weight-loss drugs beginning July 1, with qualifying beneficiaries paying as little as $50 per month under the new coverage. The landmark shift marks a significant expansion of what Medicare will cover for obesity treatment, opening the door to medications that have transformed weight management in recent years.
The $50 monthly cap makes these drugs substantially more affordable than their out-of-pocket list prices, which can run into hundreds of dollars per month without insurance. For seniors who have struggled with obesity-related conditions, the coverage represents a meaningful financial breakthrough — though eligibility requirements mean not every Medicare enrollee will automatically qualify.
Read more Four Midyear Money Moves the Wealthy Swear By →
Before filling a prescription, beneficiaries should carefully weigh the potential downsides alongside the benefits. GLP-1 medications have been associated with notable side effects, including nausea, digestive issues, and, critically, muscle loss — a concern that carries heightened risk for older adults, who are already more vulnerable to age-related muscle deterioration known as sarcopenia. Doctors may recommend pairing these drugs with resistance exercise and adequate protein intake to offset that risk.
Health experts caution that seniors should consult their physicians to determine whether they meet the qualifying criteria and to assess their individual health profiles before starting treatment. The drugs have shown strong results for weight reduction, but the long-term implications for elderly patients specifically continue to be studied.
Continue reading at MarketWatch.com
